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Cytokines are important for breast cell function, both as trophic hormones and as mediators of host defense mechanisms against
breast cancer. Recently, inducible feedback suppressors of cytokine signalling (SOCS/JAB/SSI) have been identified, which decrease
cell sensitivity to cytokines. We examined the expression of SOCS genes in 17 breast carcinomas and 10 breast cancer lines, in
comparison with normal tissue and breast lines. We report elevated expression of SOCS-1–3 and CIS immunoreactive proteins
within in situ ductal carcinomas and infiltrating ductal carcinomas relative to normal breast tissue. Significantly increased expression of
SOCS-1–3 and CIS transcripts was also shown by quantitative in situ hybridisation within both tumour tissue and reactive stroma. CIS
transcript expression was elevated in all 10 cancer lines, but not in control lines. However, there was no consistent elevation of other
SOCS transcripts. CIS protein was shown by immunoblot to be present in all cancer lines at increased levels, mainly as the 47kDa
ubiquitinylated form. A potential proliferative role for CIS overexpression is supported by reports that CIS activates ERK kinases, and
by strong induction in transient reporter assays with an ERK-responsive promoter. The in vivo elevation of SOCS gene expression
may be part of the host/tumour response or a response to autocrine/paracrine GH and prolactin. However, increased CIS expression
in breast cancer lines appears to be a specific lesion, and could simultaneously shut down STAT 5 signalling by trophic hormones,
confer resistance to host cytokines and increase proliferation through ERK kinases.
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Cytokines are key regulators of mammary epithelial cell function,
exerting regulatory actions on proliferation, differentiation,
apoptosis and immune surveillance. For example, mammary
ductal proliferation and branching is promoted by growth
hormone (Silberstein and Daniel, 1987), while alveolar cell
proliferation and secretory function require the presence of
prolactin (Vonderhaar, 1987). Epidemiologic evidence indicates a
role of prolactin in both the pathogenesis and progression of
breast cancer (Hankinson et al, 1999). However, both of these
cytokine hormones can promote proliferation of breast cancer
lines (Fuh and Wells, 1995; Kaulsay et al, 1999) and their receptors
are expressed in a wide variety of breast cancers (Clevenger et al,
1995; Mertani et al, 1998). Both can also be synthesised locally in
the mammary gland (Clevenger et al, 1995; Reynolds et al, 1997),
and antagonists of the prolactin and growth hormone (GH)
receptors are able to inhibit proliferation of breast cancer lines
(Fuh and Wells, 1995). Moreover, autocrine production of GH in
human mammary cell lines promotes the transformed phenotype
(Kaulsay et al, 1999), and prolactin increases the motility of breast
cancer lines (Maus et al, 1999).
Cytokine receptors exert their actions through activation of the
Janus kinases (JAKs), which tyrosine phosphorylate both the
receptors and their downstream signalling targets, notably the
STAT family of transcriptional activators (Argetsinger and Carter-
Su, 1996). The major STATs responsible for regulation of the
mammary gland by GH and prolactin are STAT 5a and 5b
(Teglund et al, 1998), both receptors are also able to activate STAT
3 (Argetsinger and Carter-Su, 1996). Immune cytokines such as the
interferons also utilise JAKs, and play an important role in
mediating the host response to development of breast cancer
(Allione et al, 1994; Camp et al, 1996; Tannenbaum and Hamilton,
2000).
Recently, it has been shown that cytokine signalling through the
JAK/STAT pathway is controlled by a classical feedback loop
through suppressors of cytokine signalling (SOCS/JAB/SSI)
(Hilton, 1999). Suppressors of cytokine signalling proteins are
rapidly induced by activated STATs and act to block the cytokine
signal either by direct inhibition of JAKs (SOCS-1), by binding to
tyrosine phosphorylated receptor so as to exclude binding of other
SH2 and PTB domain-containing signalling proteins such as
STATs (CIS), or by both mechanisms (SOCS-3) (Ram and
Waxman, 1999). SOCS proteins are also able to accelerate
proteasome-mediated destruction of the activated cytokine–
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particularly in the case of CIS. These inhibitory regulators not only
attenuate the signal from the activated cytokine receptor itself, but
can also decrease cell sensitivity to other cytokines and hormones,
such as insulin (Emanuelli et al, 2000). Thus, prolactin, the major
trophic cytokine for the breast, is known to rapidly induce SOCS-
1–3 and CIS, and this results in loss of sensitivity to subsequent
prolactin challenge (Tam et al, 2001). SOCS-1 has been shown to
be critical for preventing interferon g (IFNg)-mediated growth
arrest of M-1 myeloid cells (Sakamoto et al, 1998), and over-
expression of SOCS-1 or SOCS-3 in breast cancer lines inhibits the
antiviral and antiproliferative ability of IFNg (Song and Shuai,
1998). Interestingly, there is evidence that mammary carcinoma
lines are resistant to the growth inhibitory actions of IFNg (Harvat
and Jetten, 1996), which could be the result of constitutive
expression of SOCS proteins. Indeed, constitutive SOCS-3 expres-
sion has been reported for cutaneous T-cell lymphoma lines, and
reversal of this expression was associated with increased sensitivity
to interferon g inhibition of proliferation (Brender et al, 2001).
In view of the importance of SOCS expression in regulation of
mammary cell function, and its potential importance in breast
cancer, we have examined the expression of SOCS-1–3 and CIS in
both breast cancers and in breast cancer lines. The former provides
information about SOCS expression in vivo in the context of host
responses, while the latter allows for demonstration of constitutive
expression that may result from genomic alteration.
MATERIALS AND METHODS
Tissue samples
Surgical samples of breast cancer were selected from the files of
University Clinical Hospital of Santiago de Compostela (Pr.
Forteza) (Spain), which had been collected with Institutional
Ethics Committee approval. A total of 20 human breast samples
defined by standard histopathological criteria were studied: three
normals, six in situ ductal carcinomas without lymph node
metastasis, and 11 infiltrating ductal carcinomas. Tissues were
fixed in 10% buffered formalin for 24h at room temperature,
dehydrated, embedded in paraffin and sectioned by standard
procedure. Sections of 5mm thick were mounted on sterilised 3-
aminopropyl-triethoxysilane-coated slides (Sigma, St Louis, MO,
USA) and dewaxed before processing for in situ hybridisation or
immunohistochemistry.
Cell lines
The BT-20, MA-11, MDA-MB-468, SK-BR-3, KPL-1, T-47D, UACC-
893, ZR-75-1 and ZR-75-30 cell lines were obtained from American
Type Culture Collection (Manassas, VA, USA) and grown in RPMI
1640 medium supplemented with 10% FCS. The HMEC184, MCF-
10A and MCF7 cell lines were gifts from Dr R Sutherland (Garvan
Institute, Sydney, Australia). The HMEC184 cell line was grown in
MCDB 170 culture medium supplemented with bovine pituitary
extract (Gibco BRL, Rockville, MD, USA) and 5mgml
 1 gentamy-
cin. The MCF-10A cell line was grown in DMEM: Hams F12 (1:1)
supplemented with 20ngml
 1 EGF, 10mgml
 1 insulin, 500ngml
 1
hydrocortisone, 2.5mmoll
 1 L-glutamine, 5% horse serum and
5mgml
 1 gentamycin. The MCF7 cell line was cultured in RPMI
1640 medium supplemented with 10% Serum Supreme (a fetal
bovine serum alternative supplied by Biowhittaker, USA) and
5mgml
 1 gentamycin.
Probes and antibodies
Full-length cDNA probes were used to detect SOCS 1, 2 and 3, and
CIS mRNAs (Starr et al, 1997). The human prolactin receptor
probe was directed to the extracellular domain, nucleotides
346–1001 (Boutin et al, 1989). The human GH receptor probe
was also directed to the extracellular domain, nucleotides 1–720
(Godowski et al, 1989). These probes were labelled with
a[
35S]dATP (NEN Life Sciences, Boston, MA, USA) by random
priming and then purified from the free nucleotides with Nick
Columns (Amersham Pharmacia Biotech AB, Sweden) according
to the suppliers’ instructions.
Goat antibody raised against a peptide corresponding to the
carboxy terminal sequence of human SOCS-1 (cat. no. sc-7005,
C20) and to the amino-terminal sequence of human CIS (cat. no.
sc-1529, N-19) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit anti-CIS antibody was a generous
gift of Professor Yoshimura, Institute of Life Science, Kurume,
Japan (described in Matsumoto et al (1997)). Rabbit anti-SOCS-3
antibody was raised against murine SOCS-3, and was a generous
gift of Dr Doug Hilton (Walter & Eliza Hall Institute, Parkville,
Australia). The streptavidin–avidin–peroxidase complex proce-
dure was employed with diaminobenzidine as chromogen (Duet
kit, Dakopatts, Carpinteria, CA,USA).
In situ hybridisation
Dewaxed sections were digested with 5mgml
 1 proteinase K
(Roche Diagnostics, Meylan, France) in a Tris (20mmoll
 1)-CaCl2
(2mmoll
 1) buffer for 30min at 371C. The slides were dehydrated
in ethanol series and air-dried. Sections were then covered with
hybridisation buffer containing 50% deionised formamide, 10%
dextran sulphate, 4 standard saline citrate (SSC) (1 
SSC¼0.15moll
 1 NaCl, 0.015moll
 1 sodium citrate, pH 7.0),
1 Denhardt’s solution (50  Denhardt’s solution¼1% BSA, 1%
Ficoll 400, 1% polyvinylpyrolidone), 100mgml
 1 yeast transfer
RNA, 10mM dithiothreitol and labelled probe (5000d.p.m.ml
 1
corresponding to 0.1–0.5mgml
 1 of hybridisation buffer). In situ
hybridisation was performed overnight at 401C. Sections were
washed sequentially in 2  SSC for 1h at room temperature, then
for 1h at 451C and subsequently in 1  SSC, followed by 0.5  SSC
and 0.1  SSC, each for 30min at room temperature. For
macroautoradiography, dehydrated sections were apposed onto
autoradiographic films (Hyperfilm [
3H], Amersham-Pharmacia,
Orsay, France) for 1 week at room temperature. For microautor-
adiographical purposes, the slides were dipped in NTB2 nuclear
emulsion (Kodak, Paris, France), exposed at 41C for 30 days,
developed in D19 (Kodak), and finally counterstained with eosin–
haemalum. Slides were observed under a fluorescent light
microscope by epipolarisation. Controls for the specificity of the
in situ hybridisation included: (1) omission of the probe; (2)
hybridisation with a heterologous labelled POMC cDNA probe, (3)
hybridisation with undenaturated labelled cDNA probe and (4)
excess of nonlabelled probe.
Semiquantification of the in situ hybridisation
A semiquantitative analysis of gene expression was performed as
previously described (Peyrol et al, 1997; Mertani et al, 1998) on
more than six macroautoradiograms from each sample obtained
under similar conditions. Sections were run through the same
hybridisation, washing, and detection assays in order to render the
signal levels comparable for each probe. The levels of mRNA were
analysed in histopathological structures identified from contiguous
sections stained with classical haematoxylin/phloxine/saffron
(HPS). We quantified the grey level obtained on film in two
compartments of normal tissues (duct and surrounding normal
connective tissue), in infiltrating ductal breast carcinomas
(cancerous area and normal connective tissue) and in three
compartments of in situ ductal breast carcinomas (cancerous duct,
epitheliostromal interface and normal connective tissue). Normal
connective tissue was analysed as far away as possible from
the tumor. Autoradiograms were analysed under standardised
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Lyon, France). Optical densities for each sample were measured, in
homogeneous areas (5–15/autoradiogram, excluding artefacts)
and then averaged. Background signal was measured on negative
control samples and substracted from each measure. A linear
relationship (standard curve) with a slope depending on exposure
time, was found by single regression analysis between optical
density values of the standards and their corresponding radio-
activity. It was then possible to compare the different radioactivity
values for each probe used, which were expressed in arbitrary
units, by inserting the optical density value of each sample into the
standard curve equation. The levels of the signals obtained after
hybridisation were expressed as the mean7s.e. Statistical analysis
was performed using one-way analysis of variance, followed by
Student’s t-test. Differences were considered significant at Po0.05.
Northern Hybridisation
Total RNA was isolated from cell lines using TRIzol Reagent
(Gibco BRL, Rockville, MD, USA) according to the manufacturer’s
protocol. Aliquots of 20mg total RNA were denatured and
subjected to electrophoresis on a 1.2% agarose, 11% formaldehyde
gels, then transferred to HyBond N membrane (Amersham
Pharmacia Biotech, Buckinghamshire, UK). RNA was stabilised
by UV-crosslinking and baking for 30min at 801C.
32P-labelled
cDNA probes specific for SOCS-1, -2, -3 and CIS were prepared by
the random prime labelling system, Rediprime II (Amersham
Pharmacia Biotech, UK) and then purified from the free
nucleotides with Nick Columns (Amersham Pharmacia Biotech
AB, Sweden) according to the suppliers’ instructions.
The blots were prehybridised with NorthernMax prehyb/hyb
Buffer (Ambion Inc., Austin, TX, USA) for 4h at 501C before a
32P-
labelled probe was added. Blots were then hybridised for 16h at the
same temperature. After hybridisation, the blots were washed in
2 SSC/0.1% SDS at 651C for 30min, twice. Autoradiography was
then carried out at  701C using Super HR-G30 X-Ray Film (Fuji
Photo Film, Tokyo, Japan). Blots were finally stripped and
rehybridised with a
32P-end-labelled oligomer probe specific for
18S ribosomal RNA to ensure equal loading.
Immunoblot
Confluent cultures of breast cancer lines were scraped and
homogenised on ice in RIPA buffer (150mmoll
 1 NaCl, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris (pH 7.5))
with Complete protease inhibitor cocktail (Roche Molecular
Biochemicals, Mannheim, Germany; cat 1697498). Lysates were
then homogenised with a Polytron homogeniser for four 15s
pulses at maximum speed on ice, boiled for 10min with 0.5 vol of
3 Laemmli sample buffer and centrifuged at 15000 r.p.m. for
20min. Protein samples (100mg) were immunoblotted as pre-
viously described (Tam et al, 2001). After semidry transfer,
nitrocellulose membranes were blocked with TBS (pH 8.0)
containing 5% skim milk, 0.1% Tween 20 and probed with goat
anti-CIS antibody (1:250, Santa Cruz Biotechnology; cat. sc-1529)
at 41C overnight. Thereafter, membranes were incubated with HRP
conjugated rabbit anti-goat antibody (Pierce, Rockford, IL, USA)
at 1:16000 for 1h at room temperature followed by development
with West Pico Chemiluminescence Substrate (Pierce, Rockford,
IL, USA).
Immunohistochemistry
Sections were dewaxed, rehydrated and pretreated with 3% H2O2.
They were then blocked with 10% normal horse serum, followed
either by 1:500 rabbit anti-CIS antiserum (a gift from A
Yoshimura) or 1:500 rabbit anti-SOCS anti-serum (a gift of Dr
D Hilton) or 1:500 non-immune rabbit serum (as negative
control), overnight at 41C. Thereafter, sections were incubated
with 1:200 biotinylated donkey anti-rabbit IgG (cat. RPN1004,
Amersham, UK) for 2h at room temperature, followed by 1:200
streptavidin–biotinylated HRP complex (cat. RPN 1051, Amer-
sham, UK) for 2h at room temperature. The signal was visualised
by incubation with diaminobenzidine substrate for 5min. Sections
were counterstained with haematoxylin and dehydrated before
mounting.
ERK reporter assay
This was carried out in CHO cells as described in Clarkson et al
(1999) using a luciferase coding sequence downstream of an egr-1
promoter fragment comprising 624bp 50 of the initiation codon.
CHO K1 cells seeded at 3 10
5 cells per well of a six-well plate and
were transfected with DOTAP at a final DNA concentration of 4mg
per well. This comprised 1mg of the reporter construct and 0, 3, 10,
30, 100, 300, 1000 and 3000ng of the CIS expression vector
(pCDNA3). Empty vector was added to make the total up to 3mgi n
all cases. The medium was changed at 18h, the cells were then left
for 48h in 0.125% serum supreme (Biowhittaker, Walkersville,
MD, USA) in Hams’ medium before harvesting for luciferase assay
as described in Clarkson et al (1999).
RESULTS
Breast cancer tissues
In situ hybridisation: Overview Gene expression of different
SOCS and CIS mRNAs in breast disorders was visualised through
hybridisation between labelled probe and target mRNA, apparent
as variable grey levels on film (Figure 1) and bright silver grains on
tissue sections (Figure 2). The results obtained were always
qualitatively consistent. The specificity of the signal was demon-
strated by use of the controls described in the Materials and
Methods. Thus, no specific signal could be detected after
hybridisation with unrelated labelled cDNA probe or when cold
probe was used as competitor (Figure 2A, B). Expression of the
four genes was localized to identical areas but with variable
intensity as shown by the quantitative analysis (Figure 3).
Consequently, only typical results are shown (Figures 1 and 2).
Regional expression In normal breast tissue obtained at a
distance from the tumour, the macroautoradiographic hybridisa-
tion signal for SOCS-1–3 and CIS mRNA was observed in regions
corresponding to epithelial component of the duct (Figure 1B–E).
A weak, homogeneous signal associated with the whole connective
tissue area appeared to be specific in comparison to control
sections hybridised with unrelated cDNA probe (not shown) and
presumably represents the physiological level of SOCS-1–3 and
CIS expression.
Higher expression of SOCS-1–3 and CIS genes was evidenced in
ducts enlarged by tumour cell proliferation and in the periductal
reactive stroma. On sections obtained from patients with in situ
breast carcinoma, this signal decreased in connective tissue located
at a distance from the cancerous ducts (Figure 1G–J). In sections
obtained from patients with infiltrating breast carcinoma,
SOCS-1–3, and CIS transcript expression was stronger in the
region corresponding to the most active zone of the tumour
(Figure 1L–O).
Semiquantitative analysis of mRNA Relative level of SOCS-1
(Figure 3A), SOCS-2 (Figure 3B), SOCS-3 (Figure 3C) and CIS
(Figure 3D) mRNA expression was measured densitometrically on
autoradiographic films on normal and pathologic breast sections,
in areas selected as defined in Materials and Methods. Note that
the signal intensities obtained for each mRNA cannot be
SOCS gene expression in breast carcinoma
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the same efficiency.
In normal breast tissue, the hybridisation signal was stronger in
the epithelial ducts than the connective tissue, and this was seen
for all probes except SOCS-2 (Figure 3A–D). On the pathologic
sections, we consistently observed that SOCS-1–3 and CIS gene
expression was strongly associated with the tumor cells and was
significantly higher than the basal level in normal adjacent
epithelial and connective tissues (Po0.05).
SOCS-1 gene expression increased in the cancerous ducts
(þ22% vs normal ducts, Po0.05) and in the reactive stromal
area (þ104% vs adjacent connective tissue, Po0.01) of sections
obtained from patients with in situ ductal carcinoma (Figure 3A).
SOCS-2 gene expression more significantly increased in the
cancerous cells (þ135% vs normal duct, Po0.05) of in situ ductal
carcinoma, as well as in the tumoral area of infiltrating carcinoma
(þ50% vs normal duct, Po0.05) (Figure 3B). SOCS-3 gene
expression significantly increased in the cancerous ducts (þ32%
vs normal duct, Po0.05) and in the reactive stromal area (þ170%
vs adjacent connective tissue, Po0.01) of in situ ductal carcinoma,
as well as in tumour area of sections obtained from patients with
infiltrating carcinoma (þ39% vs normal duct, Po0.05)
(Figure 3C). CIS gene expression was strongly increased in tumour
cells (þ120% vs normal ducts, Po0.01) of in situ ductal
carcinoma, as well as in tumour area of sections obtained from
patients with infiltrating carcinoma (þ60% vs normal ducts,
Po0.05). CIS expression was also elevated in adjacent reactive
stroma relative to normal tissue (Figure 3D).
Cellular patterns of SOCS-1–3 and CIS gene expression To
determine which cell components expressed SOCS-1–3 and CIS
A
B
C
D
SOCS-1
SOCS-2
SOCS-3
CIS
Normal
breast tissue
E
F
G 
I
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L 
In situ ductal
carcinoma 
Invasive ductal 
carcinoma
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M 
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H
Figure 1 Macroautoradiographic pattern of ISH of SOCS-1–3, CIS
mRNA performed on sections of normal breast (A–E) and typical lesions
of in situ (F–J) and invasive (K–O) ductal carcinomas. Semiquantitative
expression of mRNA was performed on typical areas of the samples, as
illustrated in B, G and L, after precise microscopic examination of the
contiguous HPS-stained sections (A, F and K). The signal (dark areas)
corresponds to different levels of SOCS and CIS genes expression. On
adjacent sections of normal breast tissue, the signal obtained for the four
genes is localised to the ducts and lobules (arrow) (B–E). On adjacent
sections of in situ ductal carcinoma, the same intense signal is observed for
the four genes and is localized to areas corresponding to enlarged ducts
and periductal stroma reaction (arrows) (G–J). On adjacent sections of
invasive ductal carcinoma, the increased density observed with the four
probes encompasses the area corresponding to tumour cells infiltrating the
cellular stroma (L–O). Thus, a more intense signal is seen specifically
localised to the area of tumour invasion (arrow). Bar, 5mm.
I 
 
A B
C D
E FG
H J
Figure 2 Cellular expression of SOCS-1–3 and CIS mRNA in normal
breast (A, C, D), in situ (E–G) and invasive (H–J) ductal breast
carcinomas, evidenced by the presence of bright silver grains on emulsion-
coated sections. On sections of normal breast tissue, basal levels of SOCS-
1( C) and CIS (D) were detected in normal epithelial cells and in scattered
fibroblasts of the surrounding connective tissue. On sections from patients
with in situ ductal carcinoma, expression of SOCS-1 (E), SOCS-2 (F) and
CIS (G) transcripts was strongly associated with proliferative tumour cells
(arrows) of the enlarged ducts, in concentric layers of fibroblastic cells
(arrowheads) and in lymphocytes of inflammatory infiltrates (*). On
sections from patients with invasive ductal carcinoma, gene expression of
SOCS-1 (H), SOCS-3 (I) and CIS (J) was abundantly detected in the
whole area of the tumour. The close association of cancerous cells and
stromal cells prevents the precise identification of the positive cell
component. No signal was observed when in situ hybridisation was
performed with heterologous cDNA probe as a negative control on
normal breast tissue (A) and invasive ductal carcinoma (B). Bar, 50mm.
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graphic methodology was utilized as previously described (Mertani
et al, 1998). Basal levels of SOCS-1 (Figure 2C), SOCS-2, -3 (not
shown) and CIS (Figure 2D) mRNA were detected in both luminal
epithelial and myoepithelial cells of normal ducts and in scattered
fibroblasts of the surrounding normal stroma.
In sections from patients with intraductal breast carcinoma, the
expression of the four genes was localised to cancerous cells as well
as to cells of the reactive stroma surrounding the ducts (Figure
2E–G), as was evident with the macroautoradiographic study
described above (Figure 1G–J). In this reactive stroma, concentric
layers of myoepithelial and myofibroblastic cells showed an
intense signal. The stroma was often infiltrated by numerous
inflammatory cells which were also strongly labelled (Figure 2E).
As reflected by the semiquantitative data (Figure 3), there was no
difference in signal intensity between the signal obtained in the
tumour cells and the periductal reactive stroma (Figure 2E–G).
In sections obtained from patients with infiltrating ductal breast
carcinoma, gene expression of SOCS-1, -2, -3 and CIS was
associated with the entire area of the tumour invasion (Figure
2H–J). The tumour architecture and the stromal disorganization
of this type of breast cancer limited clear distinction between silver
grains associated with tumour cells and stromal cells accompany-
ing the tumour progression.
Immunohistochemistry CIS immunoreactivity was weak in nor-
mal duct luminal epithelium and myoepithelial cells, positive in
blood vessels, and strongly positive in carcinoma (Figure 4, panels
A1 and A2). Fibroblasts of connective tissue did not show
significant CIS immunoreactivity. Immunoreactivity for SOCS-3
was similar to that for CIS, with carcinoma staining more
prominent than in normal epithelium, although staining in blood
vessels was not as evident (Figure 4, panels B1 and B2). Both in the
case of CIS and for SOCS-3, no immunoreactivity was seen when
nonimmune serum was run in parallel sections (not shown).
Breast cancer lines
Northern analysis for SOCS transcripts A survey of 10 breast
cancer lines for SOCS-1–3 and CIS transcripts showed that only
CIS mRNA was elevated in all transformed lines in comparison
with the two phenotypically normal lines, HMEC184 and MCF-
10A. There was no correlation between CIS transcript expression
and GH receptor mRNA expression across these lines (Figure 5).
Prolactin receptor mRNA was expressed in all but one of the
transformed lines and not in the two control lines, but the level of
prolactin receptor expression did not correlate with the level of CIS
mRNA across these lines (Figure 5). It is possible that endogenous
or exogenous prolactin could elevate CIS transcripts in these lines,
but the lack of correlation between CIS transcript levels and
expression of other SOCS transcripts argues against this, given that
prolactin is able to induce SOCS-1,-3 and CIS transcripts in
mammary tisue (Tam et al, 2001).
Immunoblot analysis Immunoblot of cell lysates from these
breast cancer lines for CIS protein revealed a high level of
expression of bands around 47000 and 32000 for all cancer lines
(Figure 6). The 47000 bands correspond to those of the
ubiquitinylated form of CIS (Tauchi et al, 2001), and were more
intense than the 32000 band in all cases except for MDA-MB-468
and ZR 75–30 lines. These bands were absent in the MCF-10A
control line, corresponding to its lack of CIS transcripts. Note that
the FLAG tagged CIS control runs more slowly because of the
contribution from the tag.
In order to determine if expression of the CIS protein was
dependent on serum factors, including prolactin and GH, the
breast cancer lines were deprived of serum for 12h before
harvesting for immunoblot analysis. As can be seen in Figure 7,
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Figure 3 Quantification of mRNA levels was performed on macro-
autoradiograms from normal breast, in situ and invasive ductal carcinomas
as described in Materials and Methods. Optical densities were measured for
the four probes (A: SOCS-1, B: SOCS-2, C: SOCS-3, D: CIS) in typical
areas according to pathological criteria: (&), normal duct; (’), normal
connective tissue; ( ), cancerous ducts; ( ), reactive stroma; ( ), invasive
area; ( ), adjacent normal connective tissue; expressed in arbitrary
units7s.e.m. *Po0.05.
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the lines we examined.
ERK reporter assay This was carried out with a luciferase
reporter construct that possesses five SRF/Ets response elements,
which are responsive to ERK stimulation through phosphorylation
of Elk-1 and Sap1a (Gille et al, 1995; Janknecht and Hunter, 1997),
but has no STAT5 response elements (Clarkson et al, 1999). As
shown in Figure 8, transfection with an increasing level of CIS
expression plasmid results in increased ERK reporter activity. The
effect is substantial, fold inductions at 3mg CIS plasmid being 57-,
55- and 27-fold in three independent assays.
A1 
B2
B1
A2 
Figure 4 Immunostaining for CIS and SOCS-3 in normal breast tissue
and infiltrating ductal carcinoma. Tissues were fixed and processed as
described in the Materials and Methods section. Cancerous cells were
strongly immunoreactive for CIS (A1) and SOCS-3 (B1) when compared
with normal tissues (A2 and B2, respectively). Arrows indicate equal
immunoreactivity in blood vessels of normal and cancerous tissue. Bar,
100mm.
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SOCS-3
18S
hPRL-R
hGH-R
Figure 5 Expression of transcripts for CIS and SOCS-1–3 and for GH
and prolactin receptors in normal (HMEC184 and MCF-10A) and 10
breast cancer lines. Total RNA was extracted from cell lines, subjected to
electrophoresis on a formaldehyde gel and blotted on a nylon membrane.
Identical blots were run and each was hybridized with a specific cDNA
probe. The blots were then washed and exposed to X-ray films as
described in Materials and Methods. The exposure time for CIS was 2 days;
for SOCS-1, 5 days; for SOCS-2, 5 days; and for SOCS-3, 3 days. Blots
were stripped and reprobed for 18S rRNA to ensure equal loading.
MCF-10A
BT-20
MA-11
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T-47D
UACC-893
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ZR-75-30
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31.7 kDa-
42.6 kDa-
Flag-CIS
Figure 6 CIS protein expression in breast cancer lines. Total cell lysate
was obtained from confluent cultures of breast cancer lines or normal lines.
Lysates were then immunobloted and probed with goat anti-CIS antibody
as described in the Materials and Methods. FLAG-tagged CIS expressed in
HEK 293 cells was used as a positive control. Signal corresponding to the
CIS protein was detected migrating at 32kDa in breast cancer cell lines.
Another slower migrating band at 47kDa corresponds to the ubiquitiny-
lated form of CIS.
MCF-10A
SK-BR-3 
KPL-1
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+ − + − + − + − FCS
31.7 kDa−
Figure 7 Lack of effect of serum on expression of CIS protein in breast
cancer lines. Cells were exposed to 10% serum or serum starved for 12h
before harvesting for immunoblot analyses as for Figure 6.
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Figure 8 CIS transfection results in elevated ERK reporter activity. CHO
cells were transfected with increasing amounts of CIS expression plasmid
and an ERK reporter plasmid. The total amount of DNA was normalised to
3mg with empty pcDNA3. Luciferase assay was carried out as described in
the Materials and Methods section. Luciferase counts expressed as
mean7s.e.m., four replicates per point. This result was obtained on three
separate occasions.
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yDISCUSSION
The present study demonstrates that SOCS-1, -2, -3 and CIS
mRNAs are expressed more strongly in human breast carcinoma.
We have identified the cell types expressing SOCS and CIS mRNA,
and quantified the relative levels of expression in human breast
tumours of increasing severity from a preinvasive stage (ductal
carcinoma) to invasive carcinoma, for which we have previously
documented the gene expression levels for both GH and PRL
receptors (Mertani et al, 1998).
In the normal human breast, lower levels of SOCS and CIS
mRNA were found in both ductal epithelial cells and the
fibroblastic component. This level of gene expression was also
found in normal tissue located at a distance from the tumour in all
the pathologic samples examined. Our results show upregulation
of SOCS and CIS gene expression in malignant breast disorders. In
ductal breast carcinoma, SOCS-2 and CIS gene expression was
particularly strong in tumour cells within the ducts, which were
isolated from the reactive stroma by the myoepithelial barrier. This
result can be compared to the elevated CIS gene expression level
seen in vitro with breast cancer lines. Surrounding the cancerous
ducts, stronger gene expression was also evidenced in the region of
reactive stroma showing features of fibrogenesis and immune
activation. High levels of SOCS-1–3 and CIS gene expression were
associated with the fibroblasts, inflammatory cells and endothelial
cells of the neovascularisation, which essentially comprises the
reactive stroma. The local host defense is particularly important
during the progression period from in situ to invasive ductal
carcinoma and is characterised by intense cytokine production
from the lymphocytic infiltration. Thus, a study by Camp et al
(1996) performed on 89 human breast carcinomas showed strong
lymphocytic production of Il-2, Il-4, TGF-b1, TNF-a as well as
lower levels of IFNg and GM-CSF. These cytokines are major
activators of SOCS/CIS signalling, particularly SOCS-1 and -3 in
granulocytes and lymphocytes (Hilton, 1999; Dogusan et al, 2000).
In addition to the conventional inflammatory cytokines, PRL
and GH, the major mammotrophic hormones, may be involved in
SOCS gene induction during breast carcinogenesis. These are also
known to induce substantial SOCS-1–3 and CIS gene expression
(Adams et al, 1998; Tam et al, 2001). The presence of GH and PRL
receptors in both epithelial and stromal cells has been previously
shown in the normal human breast and in various benign and
malignant human breast disorders (Clevenger et al, 1995; Mertani
et al, 1998; Gebre-Medhin et al, 2001). Recent studies have shown
the importance of autocrine/paracrine production of hGH and
hPRL during human breast carcinoma cell proliferation in vitro
(Kaulsay et al, 1999; Mertani et al, 2001) and have proposed that
local production of PRL in vivo is more important than systemic
PRL for the tumour formation (reviewed in Wennbo and Tornell,
2000). We have demonstrated in vivo hGH production from
human breast carcinoma and established that increased expression
of the hGH gene occurs in the epithelial component and that de
novo stromal expression of hGH is associated with the neoplastic
progression of the mammary gland (Raccurt et al, 2002). Other
studies (Hattori et al, 1990; Wu et al, 1996) have shown that
human lymphocytes express abundant hGH mRNA. These
considerations and our present results, suggest that autocrine/
paracrine GH and/or PRL in the reactive stroma of ductal
carcinoma may be inducers of SOCS gene expression in vivo.
In order to establish whether this SOCS overexpression is
intrinsic to the transformed breast cancer cell or a result of host–
tumour interaction, we also examined 10 breast cancer lines for
SOCS gene expression. However, only CIS gene expression was
elevated in all of these lines, but not in the two control breast lines.
Immunoblots showed a high level of expression of ubiquitinylated
CIS or CIS protein in the cancer lines, whereas neither form of CIS
was detected in the control line. Level of protein expression of CIS
was not affected by serum starvation, suggesting that elevated CIS
expression is intrinsic to these breast cancer lines, and does not
require serum factors such as hGH, prolactin or colony-stimulat-
ing factors. Accordingly, there was no correlation between level of
gene expression for either hGH receptor or prolactin receptor and
CIS gene expression across these lines.
Given the ubiquitous nature of SOCS gene expression in
response to host cytokines, and the above candidate inducers, it
is not unexpected that breast tumour tissue shows elevated SOCS
expression. However, the elevation of CIS expression is indepen-
dent of host responses, and appears to be intrinsic to the breast
cancer line itself. What might be the significance of this elevation?
We suggest that it serves at least a two-fold purpose: (1) to activate
the proliferative MAP/ERK kinase pathway and (2) to block STAT
5-mediated responses to trophic hormones, which maintain
normal differentiated breast cell phenotype as exemplified by the
lack of mammary gland development in CIS transgenic mice
(Matsumoto et al, 1999). Activation of MAP kinases (ERK, JNK)
has been shown to be an important consequence of CIS
overexpression in CD4T cells (Li et al, 2000), and is thought to
be a result of direct association between CIS and PKC theta, since
this PKC is able to activate MAP kinases (Baier-Bitterlich et al,
1996). We have confirmed that chronically elevated CIS is able to
elevate ERK activity in an ERK responsive promoter assay, and
find induction of luciferase reporter activity proportional to the
amount of cotransfected CIS expression vector. A coordinated
increase in ERK activation and inhibition of STAT5 activation by
CIS could allow it to act as a switch, promoting proliferation while
blocking differentiated breast cell function. An additional role for
the constitutively elevated CIS may be to decrease breast cancer
sensitivity to interferons, similar to the decreased sensitivity to
IFNg seen in cutaneous T-lymphoma (CTCL) cell lines that
constitutively express SOCS-3 (Brender et al, 2001).
The alteration responsible for elevated CIS gene and protein
expression is unclear, but given that the major factor thought to be
responsible for induction of CIS by cytokines is STAT 5 (Verdier
et al, 1998), the increased CIS expression may be linked to escape
from STAT 5-mediated induction of its promoter. This is
supported by our preliminary studies that show low or undetect-
able STAT 5 in the breast cancer lines studied here (Tam, Lau,
Waters, unpublished). Other transcription factors have been
shown to interact with the CIS promoter such as Ets factors
GABPa/b and NFkB, and deletion of STAT 5 elements in the
proximal human CIS promoter still results in substantial levels of
basal activity (Verdier et al, 1998), so other cis acting factors may
be important in maintaining CIS expression in these breast cancer
cells.
The significance of the strongly elevated level of ubiquitinylated
CIS is unclear, but may relate to the ability of CIS to promote
destruction of cytokine–cytokine receptor complexes via the
ubiquitin-proteasome pathway (Tauchi et al, 2001). This has been
shown to substantially decrease cell sensitivity to the relevant
cytokine (Ram and Waxman, 2000; Tauchi et al, 2001).
In conclusion, we report elevation of SOCS-1–3 and CIS in
breast cancers in vivo. In breast cancer lines, only CIS gene
expression was elevated, and this could have important con-
sequences for breast cancer phenotype and proliferative ability.
Given this observation, agents blocking the production or action of
CIS could be of therapeutic benefit in breast cancer.
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